Cargando…

A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant

BACKGROUND: The perioperative management of patients taking a direct oral anticoagulant (DOAC) who require a high‐bleed‐risk surgery and/or neuraxial anesthesia is uncertain. We surveyed clinician practices relating to DOAC interruption and related perioperative management in patients having high‐bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Douketis, James D., Syed, Summer, Li, Na, Narouze, Samer, Radwi, Mansoor, Duncan, Joanne, Schulman, Sam, Spyropoulos, Alex C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845072/
https://www.ncbi.nlm.nih.gov/pubmed/33537540
http://dx.doi.org/10.1002/rth2.12430
_version_ 1783644482641592320
author Douketis, James D.
Syed, Summer
Li, Na
Narouze, Samer
Radwi, Mansoor
Duncan, Joanne
Schulman, Sam
Spyropoulos, Alex C.
author_facet Douketis, James D.
Syed, Summer
Li, Na
Narouze, Samer
Radwi, Mansoor
Duncan, Joanne
Schulman, Sam
Spyropoulos, Alex C.
author_sort Douketis, James D.
collection PubMed
description BACKGROUND: The perioperative management of patients taking a direct oral anticoagulant (DOAC) who require a high‐bleed‐risk surgery and/or neuraxial anesthesia is uncertain. We surveyed clinician practices relating to DOAC interruption and related perioperative management in patients having high‐bleed‐risk surgery with neuraxial anesthesia, and assess the suitability of a randomized trial of different perioperative DOAC management strategies. METHODS: We surveyed members of the American Society of Regional Anesthesia and Pain Medicine, the Canadian Anesthesia Society and Thrombosis Canada. We developed four clinical scenarios involving DOAC‐treated patients who required anticoagulant interruption for elective high‐bleed‐risk surgery. In three scenarios, patients were to receive neuraxial anesthesia, and in one scenario they were to receive general anesthesia. We also asked about the merit of a randomized trial to compare a 2‐day versus longer (3‐ to 5‐day) duration of DOAC interruption. RESULTS: There were 399 survey respondents of whom 356 (89%) were anesthetists and 43 (11%) were medical specialists. The responses indicate uncertainty about the DOAC interruption interval for high‐bleed‐risk surgery and/or neuraxial anesthesia; anesthetists favor 3‐ to 5‐day interruption whereas medical specialists favor 2‐day interruption. Anesthetists were unwilling to proceed with neuraxial anesthesia in patients with a 2‐day DOAC interruption interval, preferring to cancel the surgery or switch to general anesthesia. There is general agreement on the need for a randomized trial in this field to compare a 2‐day and a 3‐ to 5‐day DOAC interruption management strategy. CONCLUSIONS: There is variability in practices relating to the perioperative management of DOAC‐treated patients who require a high‐bleed‐risk surgery with neuraxial anesthesia; this variability relates to the duration of DOAC interruption in such patients.
format Online
Article
Text
id pubmed-7845072
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78450722021-02-02 A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant Douketis, James D. Syed, Summer Li, Na Narouze, Samer Radwi, Mansoor Duncan, Joanne Schulman, Sam Spyropoulos, Alex C. Res Pract Thromb Haemost Original Articles ‐ Thrombosis BACKGROUND: The perioperative management of patients taking a direct oral anticoagulant (DOAC) who require a high‐bleed‐risk surgery and/or neuraxial anesthesia is uncertain. We surveyed clinician practices relating to DOAC interruption and related perioperative management in patients having high‐bleed‐risk surgery with neuraxial anesthesia, and assess the suitability of a randomized trial of different perioperative DOAC management strategies. METHODS: We surveyed members of the American Society of Regional Anesthesia and Pain Medicine, the Canadian Anesthesia Society and Thrombosis Canada. We developed four clinical scenarios involving DOAC‐treated patients who required anticoagulant interruption for elective high‐bleed‐risk surgery. In three scenarios, patients were to receive neuraxial anesthesia, and in one scenario they were to receive general anesthesia. We also asked about the merit of a randomized trial to compare a 2‐day versus longer (3‐ to 5‐day) duration of DOAC interruption. RESULTS: There were 399 survey respondents of whom 356 (89%) were anesthetists and 43 (11%) were medical specialists. The responses indicate uncertainty about the DOAC interruption interval for high‐bleed‐risk surgery and/or neuraxial anesthesia; anesthetists favor 3‐ to 5‐day interruption whereas medical specialists favor 2‐day interruption. Anesthetists were unwilling to proceed with neuraxial anesthesia in patients with a 2‐day DOAC interruption interval, preferring to cancel the surgery or switch to general anesthesia. There is general agreement on the need for a randomized trial in this field to compare a 2‐day and a 3‐ to 5‐day DOAC interruption management strategy. CONCLUSIONS: There is variability in practices relating to the perioperative management of DOAC‐treated patients who require a high‐bleed‐risk surgery with neuraxial anesthesia; this variability relates to the duration of DOAC interruption in such patients. John Wiley and Sons Inc. 2020-12-16 /pmc/articles/PMC7845072/ /pubmed/33537540 http://dx.doi.org/10.1002/rth2.12430 Text en © 2020 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis (ISTH) This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles ‐ Thrombosis
Douketis, James D.
Syed, Summer
Li, Na
Narouze, Samer
Radwi, Mansoor
Duncan, Joanne
Schulman, Sam
Spyropoulos, Alex C.
A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant
title A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant
title_full A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant
title_fullStr A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant
title_full_unstemmed A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant
title_short A physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant
title_sort physician survey of perioperative neuraxial anesthesia management in patients on a direct oral anticoagulant
topic Original Articles ‐ Thrombosis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7845072/
https://www.ncbi.nlm.nih.gov/pubmed/33537540
http://dx.doi.org/10.1002/rth2.12430
work_keys_str_mv AT douketisjamesd aphysiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT syedsummer aphysiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT lina aphysiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT narouzesamer aphysiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT radwimansoor aphysiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT duncanjoanne aphysiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT schulmansam aphysiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT spyropoulosalexc aphysiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT douketisjamesd physiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT syedsummer physiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT lina physiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT narouzesamer physiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT radwimansoor physiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT duncanjoanne physiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT schulmansam physiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant
AT spyropoulosalexc physiciansurveyofperioperativeneuraxialanesthesiamanagementinpatientsonadirectoralanticoagulant